Biohaven Pharma
About Biohaven Pharma
220 articles with Biohaven Pharma
-
Biohaven Pharmaceutical Holding announced the acquisition of Channel Bio and new licensing rights to a spinal muscle atrophy drug from Bristol Myers Squibb.
-
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
2/25/2022
Biohaven Pharmaceutical announced today that it entered into a worldwide license agreement with Bristol Myers Squibb (NYSE: BMY) for the development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin.
-
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences
2/25/2022
Acquisition of next-generation Kv7 channel activators for target indications including epilepsy, pain disorders and affective disorders.
-
BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS
2/25/2022
Biohaven Pharmaceutical Holding Company Ltd. today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a review of accomplishments during 2021 and anticipated upcoming milestones.
-
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
2/25/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for rimegepant.
-
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
2/22/2022
Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced enrollment in a Phase 2/3 clinical trial assessing the efficacy and safety of Nurtec® ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis (CRS) with or without nasal polyps.
-
BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022
2/16/2022
Biohaven Pharmaceutical Holding Company Ltd. will hold its upcoming fourth quarter and year end 2021 earnings call and webcast, reporting financial results for the quarter ended December 31, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones, on Friday February 25, 2022 at 8:30 a.m. ET.
-
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
2/14/2022
Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. (NYSE: PFE), today announced positive top-line results from an Asia-Pacific, Phase 3 clinical trial of rimegepant in 1,431 adults for the acute treatment of migraine.
-
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports
2/3/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the publication of new findings from its long-term safety study showing reductions in migraine frequency.
-
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain
1/10/2022
Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd., along with CD3 and LICR at KU Leuven, announced that they have entered into an exclusive global license and research agreement to develop and commercialize first-in-class TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders.
-
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
1/5/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two companies.
-
BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE
12/13/2021
Biohaven Pharmaceutical Holding Company Ltd. announced today that NURTEC ODT (rimegepant) 75 mg was approved by the Ministry of Health of Israel for the preventive treatment of episodic migraine in adults.
-
Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application
12/6/2021
Biohaven today announced positive topline results from the second pivotal clinical trial (NCT04571060) evaluating the safety and efficacy of its investigational therapy, intranasal zavegepant, for the acute treatment of migraine in adults.
-
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
12/6/2021
Biohaven Pharmaceutical Holding Company Ltd. today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately.
-
The company said the study demonstrated broad efficacy, showing statistically significant superiority to placebo over a total of 15 prespecified primary and secondary outcome measures.
-
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
-
Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments
11/9/2021
Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments
-
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
11/9/2021
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
-
Biohaven and Pfizer have partnered to market the Nurtec migraine medicine outside the U. S. once approved by global regulatory organizations. Here's more about it.
-
Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021
11/4/2021
Biohaven Pharmaceutical Holding Company Ltd. will hold its upcoming third quarter 2021 earnings call and webcast, reporting financial results for the quarter ended September 30, 2021.